Macuject
Peter Girling serves as the Chief Operating Officer at Macuject, a role focused on driving growth through strategic alignment and business development in the ophthalmology software sector. As a co-founder and CEO of CELLnTEC Advanced Cell Systems AG, Peter has played a pivotal role in advancing technology in tissue engineering and regenerative medicine. Additionally, experience includes advisory roles at Tessara Therapeutics and Vert and Or, along with co-founding My Connected Health, which enhances connectivity within the healthcare system. A Business Development Manager at the Australian Medical Robotics Academy, Peter was involved in business planning and strategic partnerships in surgical robotics. With a strong academic background in Applied Science from multiple institutions, Peter's expertise spans entrepreneurship, technology transfer, and research in the life sciences sector.
This person is not in any teams
Macuject
Macuject is a clinician-driven digital health company created to end preventable blindness for tens of millions across the globe, starting with age-related macular degeneration (AMD); diabetic retinopathy, cataract and glaucoma will follow. Our innovative clinical decision support software is specifically designed to address both wet and dry forms of AMD, empowering healthcare professionals to make accurate and timely diagnoses, optimise treatment plans, and monitor disease progression more effectively. By harnessing the power of cutting-edge artificial intelligence and integrating seamlessly with existing medical infrastructure, our SaaS solutions enable early intervention and personalized care, dramatically improving patient outcomes and significantly reducing the social and economic burden of these blinding conditions. Macuject’s founder-CEO is Dr. Devinder Chauhan, a prominent Melbourne retinal specialist responsible for 8% of his state's AMD treatments. Leveraging his expertise and network, he has brought together a talented team of professionals with diverse backgrounds in commercial, technical and clinical development. Our collaborative team is dedicated to developing, refining, and promoting our ground-breaking products, ensuring both their clinical relevance and market adoption.